Organogenesis Holdings Inc at Morgan Stanley Global Healthcare Conference Transcript
All right, welcome, everyone, to the Morgan Stanley Healthcare Conference. I'm Drew Ranieri, one of the medical device analyst here. It's my pleasure to host this session with Organogenesis. I'm delighted to have Gary Gillheeney, the CEO and Chairman; and David Francisco, the CFO. Before we jump into it, just a brief disclaimer for important disclosures, please see the Morgan Stanley research disclosure website at morganstanley.com/researchdisclosures. With that out of the way, reimbursement is really kind of the first topic -- coverage and reimbursement is kind of the first topic that I wanted to cover today. And if we kind of circle back or I think back to last year, the elephant in the room was the CMS proposed rule for the physician office.
And now it's really kind of the recent LCD from 3 MACs, which kind of is complicating the wound care industry and potentially soon your operations.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
